Strongest evidence: The most robust finding comes from 16 studies showing that vitamin D supplementation increases 25-hydroxyvitamin D levels, with 14 reporting beneficial effects (evidence strength: high). Moderate evidence supports improved insulin sensitivity (6 of 9 studies beneficial, doses 1000–4000 IU/day), reduced C-reactive protein (5 of 8 studies, moderate effect), reduced interleukin-6 (5 of 8 studies, moderate effect), and improved quality of life (6 of 6 studies, small effect). Additional moderate-strength outcomes include reduced triglycerides (4 of 7 studies), reduced tumor necrosis factor alpha (3 of 5 studies), reduced HOMA-IR (3 of 5 studies), and reduced parathyroid hormone (3 of 4 studies).
Mixed or weaker evidence: No outcomes reached low or very low evidence strength within the top 12 syntheses. However, several moderate-strength outcomes show inconsistency: reduced depression symptoms (3 of 4 studies beneficial, but with small effects and methodological limitations), reduced triglycerides (3 of 7 studies neutral), and reduced interleukin-6 (3 of 8 studies neutral). The evidence tends to be more consistent in clinical or deficient populations.
Effective dose patterns: Across outcomes, effective daily doses commonly fall between 1,000 and 4,000 IU per day. For insulin sensitivity, the range is 1000–4000 IU/day; for quality of life, 4000 IU/day or 60,000 IU/week; for parathyroid hormone reduction, up to 5,000 IU/day; and for insulin levels, 1000 IU/day. Weekly bolus doses (e.g., 50,000–60,000 IU) were also used in some studies on 25-hydroxyvitamin D levels and quality of life.
Population insights: The benefits of vitamin D supplementation are most consistently observed in individuals with low baseline vitamin D status and in clinical populations, such as those with PCOS, gestational diabetes, type 2 diabetes, obesity, metabolic conditions, inflammatory diseases (e.g., rheumatoid arthritis), and older adults. Effects are often modest or absent in replete or healthy populations. Specific groups studied include women with PCOS or gestational diabetes, overweight/obese children, and patients with Alzheimer’s disease, fibromyalgia, or chronic urticaria.
Notable caveats: Across syntheses, publication bias is a recurring concern—null results are less likely to be published, potentially overestimating benefits. Many studies combined vitamin D with other supplements (e.g., magnesium, whey protein), making it difficult to isolate its independent effect. Dose and form reporting were inconsistent; where specified, vitamin D3 (cholecalciferol) was used. Most trials lasted 8–12 weeks, so shorter durations may not capture effects. Several outcomes had small sample sizes or neutral studies, and clinical significance of small effect sizes remains uncertain.